- Home
- IMPP vs THTX Comparison
IMPP vs THTX Comparison
Compare IMPP & THTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMPP
- THTX
- Stock Information
- Founded
- IMPP 1981
- THTX 1993
- Country
- IMPP Greece
- THTX Canada
- Employees
- IMPP N/A
- THTX N/A
- Industry
- IMPP Marine Transportation
- THTX Biotechnology: Pharmaceutical Preparations
- Sector
- IMPP Consumer Discretionary
- THTX Health Care
- Exchange
- IMPP Nasdaq
- THTX Nasdaq
- Market Cap
- IMPP 103.9M
- THTX 119.1M
- IPO Year
- IMPP N/A
- THTX N/A
- Fundamental
- Price
- IMPP $3.10
- THTX $3.18
- Analyst Decision
- IMPP
- THTX Hold
- Analyst Count
- IMPP 0
- THTX 1
- Target Price
- IMPP N/A
- THTX N/A
- AVG Volume (30 Days)
- IMPP 382.8K
- THTX 647.1K
- Earning Date
- IMPP 08-26-2025
- THTX 07-14-2025
- Dividend Yield
- IMPP N/A
- THTX N/A
- EPS Growth
- IMPP N/A
- THTX N/A
- EPS
- IMPP 1.21
- THTX N/A
- Revenue
- IMPP $138,368,325.00
- THTX $88,666,000.00
- Revenue This Year
- IMPP $8.79
- THTX N/A
- Revenue Next Year
- IMPP $40.11
- THTX $15.13
- P/E Ratio
- IMPP $2.56
- THTX N/A
- Revenue Growth
- IMPP N/A
- THTX 13.52
- 52 Week Low
- IMPP $2.12
- THTX $1.12
- 52 Week High
- IMPP $4.55
- THTX $3.20
- Technical
- Relative Strength Index (RSI)
- IMPP 51.26
- THTX 75.50
- Support Level
- IMPP $3.02
- THTX $2.28
- Resistance Level
- IMPP $3.16
- THTX $2.62
- Average True Range (ATR)
- IMPP 0.23
- THTX 0.10
- MACD
- IMPP -0.05
- THTX 0.03
- Stochastic Oscillator
- IMPP 10.39
- THTX 94.21
About IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.